Moderna, Novavax and Valneva have joined COVIDRIVE, a public-private partnership for COVID-19 vaccine effectiveness monitoring in Europe.

08/02/2022 – Three new vaccine companies (Moderna, Novavax and Valneva) have joined the COVIDRIVE consortium and officially become COVIDRIVE partners. Moderna, Novavax and Valneva will further contribute to the assessment of the effectiveness of COVID-19 vaccines in Europe to support the region’s public health response and address the vaccine companies’ regulatory obligations.

With the inclusion of these three newcomers, COVIDRIVE, which brings together public institutions, small and medium-sized enterprises and vaccine companies, has a total of 11 partners.

The new COVIDRIVE partners reflected on their participation in the consortium and the value of multi-stakeholder initiatives to monitor the effectiveness of the COVID-19 vaccines.

First, Dr Jacqueline Miller, Moderna’s Senior Vice President and Therapeutic Area Head, Infectious Disease Development, explained: “We are pleased to join the COVIDRIVE consortium and contribute to this collaboration advancing global public health. We believe that public-private partnerships play a key role in combatting the COVID-19 pandemic. As a global company, it is critical to understand data from all geographies because as we have seen throughout this pandemic, what affects one part of the world, can soon affects others. Assessing vaccine effectiveness through real-world evidence is an important tool as we try to remain ahead of the virus as it evolves.”

Moreover, Dr Seth Toback, Senior Vice President, Global Medical Affair at Novavax, commented: “Novavax is proud to join COVIDRIVE and partner across the healthcare sector in our efforts against COVID-19. We believe it is important to have multiple vaccine options available for people, particularly as we assess the need for boosters, annual revaccination, and reaching the paediatric population. This is an exciting development as we continue to work towards the development of life-saving vaccines and fight against the ongoing pandemic.”

Finally, Dr Judith Perez Gomez, Valneva’s Vice-President of Medical Affairs pointed out that “Public-private partnerships have proven to be extremely valuable for enabling R&D innovation and are even more important today as we fight the COVID-19 pandemic. We are extremely pleased to join COVIDRIVE and support Europe’s public health response through the assessment of vaccine effectiveness.”

About Moderna

Moderna is a biotechnology company based in Cambridge, Massachusetts (United States) pioneering messenger RNA (mRNA) therapeutics and vaccines. The Moderna COVID‑19 vaccine, codenamed mRNA-1273 and sold under the brand name Spikevax, received the emergency use authorisation by the U.S. Food and Drug Administration (FDA) in December 2020 and conditional marketing authorisation in the European Union by the European Medicines Agency (EMA) in January 2021. More information: www.modernatx.com.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company’s proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company’s COVID-19 vaccine, has received authorization from multiple regulatory authorities globally, including Conditional Marketing Authorization from the European Commission and Emergency Use Listing from the World Health Organization. The vaccine is also under review by multiple regulatory agencies worldwide. More information:www.novavax.com.

About Valneva

Valneva is a specialty vaccine company based in Saint-Herblain (France) focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva has developed an inactivated, adjuvanted vaccine candidate against COVID-19, VLA2001, which is currently under rolling review by the EMA. More information: www.valneva.com.

About COVIDRIVE

COVIDRIVE is a public-private partnership launched in 2021 to address the joint need to monitor COVID-19 vaccination programmes for public health institutes in Europe and to assess brand- specific COVID-19 vaccine effectiveness (CVE) for the companies as part of their regulatory obligations. For more details on COVIDRIVE please check our website www.covidrive.eu.

If you would like to request a COVID-19 vaccine effectiveness study and/or participate as a partner/study site in COVIDRIVE, send an email to the following address: info@covidrive.eu